EMA: new indication for Cabometyx for first-line treatment of advanced renal cell carcinoma in adults
The European Medicines Agency ( EMA ) has validated the application for variation to the Cabometyx ( Cabozantinib ) marketing authorization for the addition of a new indication in first-line treatment ...
read article